CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 58 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06877585
NCT06877585N/ACompleted

Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels in Hemodialysis Patients

Tungs' Taichung Metroharbour Hospital·observational·Posted Mar 14, 2025·Updated May 13, 2026

In Brief

An observational study for Dysbiosis. Completed, enrolled 58 participants across 1 site.

Detailed Summary

Gut dysbiosis is frequently characterized by decreased microbial diversity and alterations in the abundance of certain microbial species. In individuals with chronic kidney disease (CKD), dysbiosis and metabolic imbalances are prevalent, contributing to the buildup of gut-derived retention solutes and metabolites in the bloodstream. Research has consistently shown that CKD patients exhibit lower levels of beneficial gut bacteria. However, the specific functional changes in gut microbiota and their interactions with levels of uremic toxins in hemodialysis (HD) patients remain incompletely understood. This study seeks to explore the association of fecal metagenomics and targeted metabolomics in a cohort of 60 patients with different levels of to characterize the complex interplay between the gut microbiome and fecal and serum metabolites.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDysbiosis
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
2026
First PostedMar 14, 2025
Enrollment StartApr 1, 2025
Primary CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.3 years ago